Clinical Trial Update: A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes) [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating ESN364 for vasomotor symptoms (hot flashes) in postmenopausal women has completed, with results posted on 2021-09-29.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hot Flashes
• Menopause

Drugs mentioned

• ESN364

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Menopause, Hot Flashes | Phase 2 | Status: COMPLETED | Results posted: 2021-09-29